Nowadays, left ventricular assist devices are usually designed as high-speed, electric, rotary blood pumps. The pump drains blood from the left ventricular apex via an inlet cannula and ejects into the aortic root via an outlet conduit. To develop a high-performance pump, the present study utilizes partial differential equations to generate a surface representation of the impeller of the blood pump. Flow analysis around the impeller is performed by using the finite volume method to solve the fully incompressible three-dimensional Navier-Stokes equations along with the k-epsilon turbulence model. The numerical results highlight flow features in the end-wall region of the pump, namely the clearance leakage cross-flow, and the vortex associated with this leakage. These secondary flows induce major energy losses in the pumping device. On the test study, a test loop was proposed to measure the performance characteristics. It was shown that the design would provide a flow rate of 4.4 l/min with a pressure head of 122 mmHg. The DC motor power under these conditions was about 6 W and the rotational speed was 4500 rpm. Both the flow rate and head can satisfy the demand for the left artificial heart to work normally.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10047-003-0205-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Left ventricular elastance with resting volumetric transthoracic echocardiography identifies different phenotypes in heart failure with preserved ejection fraction: A retrospective analysis of a multicenter prospective observational study.
J Am Soc Echocardiogr
January 2025
Cardiology Clinic, University Center Serbia, Medical School, University Clinical Center Serbia, University of Belgrade, Serbia.
Background: Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous entity including patients with different phenotypes of near normal, normal, and supernormal left ventricular (LV) function.
Objectives: To assess the value of resting LV elastance (also known as force) with transthoracic echocardiography (TTE) to identify HFpEF phenotypes.
Methods: In a prospective, observational, multicenter study, 2380 HFpEF patients were recruited from July 2016 to May 2024.
Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial.
Lancet Diabetes Endocrinol
January 2025
British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK. Electronic address:
Background: Data on the effect of mineralocorticoid receptor antagonist therapy on HbA levels and new-onset diabetes are conflicting. We aimed to examine the effect of oral finerenone, compared with placebo, on incident diabetes in the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients with Heart Failure (FINEARTS-HF) trial.
Methods: In this randomised, double-blind, placebo-controlled trial, 6001 participants with heart failure with New York Heart Association functional class II-IV, left ventricular ejection fraction 40% or higher, evidence of structural heart disease, and elevated N-terminal pro-B-type natriuretic peptide levels were randomly assigned to finerenone or placebo, administered orally.
Prognostic value of systemic immune-inflammation index in older patients with acute coronary syndrome.
Coron Artery Dis
January 2025
Department of Cardiology, University of Health Sciences, Şişli Hamidiye Etfal Education and Research Hospital, Istanbul, Turkey.
Objectives: Contemporary studies assessing the importance of the systemic immune-inflammation index (SII) in older patients presenting with acute coronary syndrome (ACS) are scarce. This study investigated the impact and prognostic value of the SII regarding long-term mortality in older patients with ACS.
Methods: The study included 401 older patients aged 75 years and above admitted with ACS between May 2015 and December 2022.
Background: The purpose of this study was to investigate whether circulating pyruvate kinase M2 (PK-M2) levels are elevated in the peripheral blood and to assess their association with diagnosis and prognosis in patients with heart failure (HF).
Methods And Results: We conducted a prospective investigation involving 222 patients with HF and 103 control subjects, measuring PK-M2 concentrations using ELISA. The primary outcome, assessed over a median follow-up of 2 years (interquartile range: 776 to 926 days), was the time to the first occurrence of either rehospitalization for worsening HF or cardiovascular death.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!